Target Audience
This educational activity is designed to meet the needs of cardiologists and cardiac nurses treating patients with hypercholesterolemia in their clinical practice.

Statement of Need/Program Overview
Cardiologists play a significant role as clinicians who specialize in treating patients with hypercholesterolemia and related coronary/vascular complications. Given the prevalence of atherosclerotic cardiac and vascular disease and hypercholesterolemia in the United States, there is a continuing need to educate these physicians on the most recent innovations for treatment of hypercholesterolemia and the implications of the 2013 ACC/AHA guideline update. With a barrage of updated guidelines for disease management and key clinical trial results, clinicians are often overwhelmed and may not apply this information into clinical practice. Many cardiologists are also hesitant to change from standard therapy for treating hypercholesterolemia. This educational program narrows the knowledge gap and prepares the cardiologist for innovations in the treatment of lipid disorders.

Educational Objectives
After completing this activity, the participant should be better able to:

- Explore the relationship between low-density lipoprotein cholesterol levels and cardiovascular risk, emphasizing the need to utilize the appropriate treatment intensity of statin therapy based on cardiovascular risk assessment
- Review the mechanism of PCSK9 and PCSK9 inhibition in lipid metabolism
- Review the effects of PCSK9 inhibitors on the lipid profile
- Identify difficult-to-treat patient cohorts—including patients with heterozygous familial hypercholesterolemia, statin intolerance, and statin resistance—and their response to PCSK9 inhibition
- Review the phase III clinical trial data evaluating safety and efficacy of PCSK9 inhibitors and the impact on cardiovascular events

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and MRCME. Global is accredited by the ACCME to provide continuing medical education for physicians.

*This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

Faculty
Norman E. Lepor, MD, FACC, FAHA, FSCAI
Geffen School of Medicine-UCLA Cedars-Sinai Heart Institute, Los Angeles, CA

Dean J. Kereiakes, MD, FACC, FSCAI
The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH

Term of Offering
This activity was released on January 30, 2015, and is valid for 1 year. Requests for credit must be made no later than January 29, 2016

Instructions for Obtaining Credit
In order to receive credit, participants must complete the post-test electronically by visiting mrcme-online.com and entering code card004 to access the post-test.

System Requirements
PC

- Microsoft Windows 2000 SE or above
- Flash Player Plugin (>7.0.1.9 or greater)
- Internet Explorer (<5.5 or greater), or Firefox

MAC

- MacOS 10.2.8
- Flash Player Plugin (>7.0.1.9 or greater)
- Safari

*Required to view printable (PDF) version of the lesson.

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

<table>
<thead>
<tr>
<th>Name of Faculty or Presenter</th>
<th>Reported Financial Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norman E. Lepor, MD, FACC, FAHA, FSCAI</td>
<td>Grant / Research Support: Sanofi / Regeneron, Amgen Honoraria: Sanofi / Regeneron</td>
</tr>
<tr>
<td>Luann Contreras, BS</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Chirag Desai, MD</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Dean J. Kereiakes, MD, FACC, FSCAI</td>
<td>Nothing to disclose</td>
</tr>
</tbody>
</table>

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partner have with commercial interests related to the content of this CME activity:

<table>
<thead>
<tr>
<th>Name of Planner or Manager</th>
<th>Reported Financial Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley Marostica, RN, MSN</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Amanda Glazier, PhD</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Andrea Funk</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Merilee Croft</td>
<td>Nothing to disclose</td>
</tr>
</tbody>
</table>

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and MRCME do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia

Norman E. Lepor, MD, FACC, FAHA, FSCAI,1,2 Laurn Contreras, BS,2 Chirag Desai, MD,2 Dean J. Kereiakes, MD, FACC, FSCAI3
1The David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center, Los Angeles, CA; 2Westside Medical Associates of Los Angeles, Beverly Hills, CA; 3The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability in developed nations, and it is rising rapidly in other parts of the developing world. Levels of low-density lipoprotein cholesterol (LDL-C) are directly correlated with atherogenic risk, and statin-based therapy is the most common management for these patients. However, many patients exhibit resistance to and/or adverse effects from statin therapy, and there is a need for adjunctive therapies or statin alternatives for these patients. The recently discovered human protein proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in LDL-C metabolism. PCSK9 promotes LDL receptor (LDL-R) degradation with a consequent reduction in LDL-R density and an increase in LDL-C levels. Consequently, PCSK9 inhibition to reduce LDL-C levels has become a primary focus for drug development. Numerous clinical trials focusing on monoclonal antibodies against PCSK9 have demonstrated efficacy equal to or greater than statin therapy for lowering LDL-C levels. Long-term trials are underway to assess safety, tolerability, and ability to reduce ASCVD.


© 2015 MedReviews®, LLC

KEY WORDS
Hypercholesterolemia • PCSK9 • Low-density lipoprotein cholesterol • Atherosclerotic cardiovascular disease • Anti-PCSK9 monoclonal antibodies

Atherosclerosis is caused primarily by dyslipidemia and other risk factors that promote cholesterol deposition in the arterial intima.1 In most patients, low-density lipoprotein cholesterol (LDL-C) appears to account for the vast majority of atherogenesis risk. An estimated 57 million US adults age ≥ 20 years (25.3%) have plasma LDL-C levels ≥ 160 mg/dL.2 Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability in the United States and developed nations, and prevalence is rising rapidly in other parts of the developing world.
The Framingham Heart Study was the first to show a correlation between elevated total cholesterol and LDL-C with ASCVD-related events.\(^3\) Results from numerous randomized clinical trials (RCTs) of both statin and nonstatin treatments over several decades have also shown a reduced ASCVD incidence with therapies that lower LDL-C.\(^4\)\(^-\)\(^8\) Specifically, results have shown elevated LDL-C levels are causally related to atherosclerosis and lowering LDL-C levels will decrease ASCVD events and mortality in proportion to the degree of LDL-C lowering.\(^4\)\(^-\)\(^9\)

Statins are currently the most effective commercially available agents for reducing LDL-C levels; an estimated 20 million patients have been prescribed this treatment. In statin secondary prevention trials, coronary heart disease (CHD) event rates were directly proportional to on-treatment LDL-C levels obtained during treatment, demonstrating a causal link to atherosclerosis risk (Figure 1). ASCVD risk declines progressively with lower “on-statin treatment” LDL-C levels (Figure 2).\(^10\)

Epidemiologic data have shown an inverse relationship between high-density lipoprotein cholesterol (HDL-C) levels, as well as a direct relationship between triglyceride levels and ASCVD risk. Cardioprotective effects of HDL-C have been attributed to several factors,\(^11\) including reverse cholesterol transport, effects on endothelial cell function, and antioxidant activity. However, clinical trial outcomes evaluating HDL-C–targeted therapies, including niacin, fibric acid derivatives, and cholesteryl ester transfer protein (CETP) inhibitors, have lacked strength and consistency in comparison with LDL-C reduction.\(^11\) The ongoing Reduction of Cardiovascular Events with EPA-Intervention (REDUCE-IT) trial is evaluating the omega-3 fish oil icosapent ethyl and its impact on cardiovascular (CV) events.\(^12\)

**Evidence of Need: Looking Beyond Statins**

**Heterozygous Familial Hypercholesterolemia**

Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic diseases, with a prevalence of 1 in 200 to 1 in 500 individuals,\(^13\) and is characterized by extremely high levels of LDL-C, premature atherosclerosis, and CV disease.\(^14\) A diagnosis of HeFH is made in only 1% of afflicted patients, and many are not identified until they have had a cardiac event. Through careful clinical observation and genetic analysis, individuals with HeFH can be identified. Diagnosis in the clinical setting begins with obtaining a full individual and family medical history. A strong family history of elevated and therapy-resistant total cholesterol and LDL-C levels in one parent and early onset of CHD or premature myocardial infarction (MI) should raise suspicion of a HeFH.\(^13\)\(^,\)\(^15\) An individual medical history of HeFH is likely to include elevated total and LDL-C levels, premature CHD, physical evidence
of cholesterol deposits, or a history of Achilles tendonitis.\textsuperscript{16}

Lipid analysis with the presence of severe LDL-C elevation (LDL-C > 250 mg/dL in adults or LDL-C > 200 mg/dL in individuals age < 20 years) and severe elevation of total cholesterol (> 310 mg/dL in adults or > 230 mg/dL in individuals age < 20 years) in the absence of secondary causes of hyperlipidemia can further indicate possible HeFH.\textsuperscript{13,17,18} Lipid analysis in individuals with HeFH will reveal confirmation. Other studies that evaluate heart function or cardiac stress testing may yield abnormal results, suggestive of premature ischemic heart disease.\textsuperscript{15}

Clinical parameters for identification of HeFH require genetic analysis for a definitive diagnosis, so that other genetic mutations, such as familial ligand defective apolipoprotein B-100 that share the physical manifestations and elevated lipid measurements of HeFH, are excluded.\textsuperscript{20} Molecular testing will demonstrate a pathogenic defect in the \textit{LDLR} or \textit{APOB} genes.\textsuperscript{20} The presence of a functional mutation in one copy of the \textit{LDLR} gene yields a definitive diagnosis of HeFH.

Despite aggressive lipid-lowering therapy (LLT), many patients with HeFH still have LDL-C > 100 mg/dL, and even more have LDL-C > 70 mg/dL.\textsuperscript{13,14} Statin therapy is often insufficient for these patients to achieve LDL-C treatment goals.\textsuperscript{21}

Statin Intolerance
Of the general population of patients who have dyslipidemia and coronary risk, an estimated 10\% to 20\% cannot tolerate either statins or the statin dose required to achieve current LDL-C guideline goals. Adverse side effects from statins are relatively common, limiting or preventing their use in many patients.

relatively normal to slightly elevated triglyceride levels. Should an elevated triglyceride level be present in conjunction with both elevated total and LDL-C, diagnosis of HeFH should be approached with caution.\textsuperscript{19}

Further diagnosis can be accomplished through physical examination with identification of cholesterol deposits on the skin and tendons (xanthomas), eyelids (xanthelasmas), and/or cornea of the eye (corneal arcus). Tendon xanthomas occur in approximately 40\% of HeFH patients over age 40 years,\textsuperscript{19} and appear to be isolated to the Achilles tendon and metacarpal phalangeal extensor tendons of the hand. Because xanthomas may not be apparent by visual inspection, palpitation will reveal diffusely thickened tendons suggestive of xanthomas. Tendon xanthomas of the metacarpal phalangeal joints may seem more apparent by visual inspection with flexing of the digits to observe nodules that move with the tendon motion, thereby distinguishing xanthomas from existing subcutaneous nodules.\textsuperscript{15,18} Xanthomas may be imaged using sonography for further testing.

Anti-PCSK9 Monoclonal Antibodies

Overcoming Statin Resistance
Insufficient control of LDL-C and non–HDL-C levels may be exacerbated by diabetes, metabolic syndrome, or other factors that elevate ASCVD risk and/or non–HDL-C, such as HeFH, or in individuals with other genetic defects (eg, single nucleotide polymorphisms at \textit{SORT1}/\textit{CELSR2}/\textit{PSRC1} and variants at the \textit{APOE} and \textit{LPA} loci).\textsuperscript{24,26} Most currently available non–statin lipid medications, including niacin, fibrates, and CETP inhibitors, reduce LDL-C by 10\% to 20\%. Although these therapies are compatible with statins, they have not been associated with significant reductions in ASCVD events in previous clinical trials. Ezetimibe, which inhibits the Niemann-pick CI-like 1 protein, functions as a sterol transporter to mediate intestinal cholesterol absorption and counterbalances hepatobiliary cholesterol excretion. When added to 40 mg of simvastatin in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study for patients with a recent acute coronary syndrome (ACS), ezetimibe reduced the composite CV event rate (CV death, MI, documented unstable angina requiring hospitalization, coronary revascularization > 30 days, or stroke) by 6.4\% (\textit{P} = .016).\textsuperscript{17,28} This represents a modest reduction of CV events corresponding to the modest additional reduction of LDL-C obtained with ezetimibe. The 2013 American College of Cardiology/American Heart Association (ACC/AHA)
Anti-PCSK9 Monoclonal Antibodies continued

Figure 3. Achieved low-density lipoprotein cholesterol by very high cardiovascular risk categories, including those with recent acute coronary syndrome (ACS), history of coronary events, history of ischemic stroke, and history of peripheral arterial disease (PAD). Data from Ray KK et al. ISPOR 16th Annual European Congress; November 2-6, 2013; Dublin, Ireland.

Percentage

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Recent ACS</th>
<th>History of Coronary Events</th>
<th>History of Ischemic Stroke</th>
<th>History of PAD</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;70 mg/dL</td>
<td>5</td>
<td>17</td>
<td>39</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>≥70 to &lt;100 mg/dL</td>
<td>9</td>
<td>20</td>
<td>37</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>≥100 to &lt;130 mg/dL</td>
<td>8</td>
<td>20</td>
<td>22</td>
<td>40</td>
<td>36</td>
</tr>
<tr>
<td>≥130 to 160 mg/dL</td>
<td>4</td>
<td>39</td>
<td>20</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>≥160 mg/dL</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>9</td>
</tr>
</tbody>
</table>

Cholesterol guidelines state that no statin adjuncts have a favorable risk-to-benefit ratio will need to be revised. These data are consistent with the premise that “lower is better” with respect to LDL-C.

Ray and colleagues reviewed the primary findings of a British survey investigating an LDL-C treatment goal of < 70 mg/dL in high- and very-high-CV risk patients (Figure 3). High-risk CV patients were identified as those with recent ACS, or a history of prior coronary events, ischemic stroke, or peripheral artery disease. Overall, 27% of patients from The Health Improvement Network database achieved LDL-C levels < 70 mg/dL; an additional 40% achieved LDL-C levels between 70 and < 100 mg/dL, and the final third achieved LDL-C levels ≥ 100 mg/dL. The LDL-C findings were similar across all listed types of high-risk CV conditions. Approximately two-thirds of patients with a condition indicating very-high CV risk (eg, ACS) did not reach the treatment target LDL-C goal of < 70 mg/dL. These data emphasize the need for ongoing efforts to improve prescription of appropriate additional LLTs and to identify new therapies for improving LDL-C goal attainment, particularly among high-risk patients.

PCSK9 Protein

Protein convertase subtilisin/kexin type 9 (PCSK9) is a naturally occurring protein that targets the LDL receptor (LDL-R) for degradation by creating a PCSK9–LDL-R receptor complex. The LDL-R located on the hepatocyte cell surface mediates LDL-C endocytosis and all atherogenic lipoproteins by recognizing apolipoproteins B and E. PCSK9 is a key determinant of hepatic LDL-R density through its effect on LDL-R catabolism. PCSK9 promotes lysosomal degradation of intracellular LDL-R and, thus, prevents LDL-R recycling with a consequent reduction in hepatocellular surface membrane LDL-R density.

Function and Physiology

The role of PCSK9 in modulating lipid metabolism was first identified in 2003. A case of autosomal-dominant familial hypercholesterolemia was defined in relation to the gene encoding PCSK9. Additional studies in genetically modified animals (knock-out model) demonstrated that PCSK9 loss of function resulted in decreased LDL-C levels. Sequencing of the PCSK9 gene in individuals with low LDL-C found that those with loss-of-function PCSK9 mutations had a 28% lower LDL-C level compared with individuals with no mutation. A relative 88% decrease in ASCVD events was observed in 15-year follow-up in these patients. Gain-of-function mutations in PCSK9 reduced hepatic LDL-C receptors and resulted in higher plasma LDL-C levels. PCSK9 mRNA levels are responsive to cellular cholesterol levels through the transcription factor sterol regulatory element-binding protein-2 (SREBP-2). Furthermore, statins also upregulate PCSK9 synthesis, which may counterbalance their primary objective to increase LDL-R.

PCSK9 binds to the epidermal growth factor-like repeat A domain of the LDL-R, stimulating LDL-R degradation (Figure 4). When this complex is internalized in the clathrin-coated endosomes, the LDL-R bound to PCSK9 undergoes lysosomal degradation. By targeting the LDL-R, PCSK9 reduces receptor...
to inhibit PCSK9 binding to the LDL-R is an intuitively attractive option to lower LDL-C levels.

**PCSK9 Inhibition Process**

Monoclonal antibody (mAb)-mediated mechanisms have been...
the primary focus for PCSK9 inhibition, and have demonstrated greater efficacy for lowering LDL-C than statins in clinical trials. These mAbs appear to be well tolerated and safe in clinical trial experience to date. Non-antibody PCSK9 inhibition compounds also exist. These include adnectins, therapeutic proteins that bind to targets with very high affinity and specificity (similar to antibodies) but are easier to genetically manipulate, and antisense oligonucleotides (small interfering RNA), compounds that inhibit PCSK9 gene expression and synthesis.

The PCSK9 mutation was originally found in autosomal-dominant HeFH individuals, and identified as the gene coding for PCSK9. Loss of PCSK9 function resulted in a relatively modest 15% to 28% decrease in plasma LDL-C, but a striking 47% to 88% reduction in CHD events. This greater degree of CV event reduction than anticipated was explained, in part, by a lifetime exposure to lower LDL-C levels.

Two population studies have shown the beneficial effects of loss-of-function PCSK9 mutations on LDL-C levels and CV outcomes (Table 1). Individuals with loss-of-function mutations in PCSK9 or total lack of PCSK9 have naturally low LDL-C levels and a reduced risk of CHD. These patients are also generally healthy with no other apparent metabolic abnormalities.

### PCSK9 Inhibitor Clinical Trials

A number of PCSK9 mAb pharmaceuticals are in development, with the greatest clinical trial data available for evolocumab (AMG 145; Amgen, Thousand Oaks, CA), alirocumab (REGN727; sanofi-aventis, Bridgewater, NJ, and Regeneron, Tarrytown, NY), and bococizumab (RN316; Pfizer, New York, NY).

#### Alirocumab Clinical Trials

Several phase II clinical trials have demonstrated LDL-C-lowering efficacy of PCSK9 mAb inhibitors (Table 2) with relatively limited and mild treatment-associated adverse effects (eg, injection site reactions, diarrhea, fatigue, and headache).

McKenney and colleagues evaluated the LDL-C-lowering efficacy of alirocumab versus placebo following 12 weeks of therapy in patients with LDL-C ≥ 100 mg/dL who were receiving stable atorvastatin therapy of 10 to 40 mg/d. When added to atorvastatin, alirocumab further reduced LDL-C by 40% to 72% when administered in doses of 50 mg or 150 mg every 2 weeks, respectively.

Roth and associates evaluated 92 patients who had LDL-C levels ≥ 100 mg/dL after treatment with atorvastatin, 10 mg, for at least 7 weeks in a phase II, multicenter, double-blind, placebo-controlled trial. The patients were randomly assigned to receive 8 weeks of treatment with atorvastatin, 80 mg/d, plus alirocumab once every 2 weeks, atorvastatin, 10 mg, plus alirocumab once every 2 weeks, or atorvastatin, 80 mg/d, plus placebo once every 2 weeks. The least-squares mean (± standard error) percentage reduction from baseline for LDL-C was 73.2 ± 3.5% with atorvastatin, 80 mg, plus alirocumab versus 17.3 ± 3.5% with atorvastatin, 80 mg, plus placebo (P < .001) and 66.2 ± 3.5% with atorvastatin, 10 mg, plus alirocumab.

Stein and associates assessed efficacy and safety of various alirocumab doses and dosing intervals added to maximally tolerated statins with or without ezetimibe to lower LDL-C in HeFH patients. Mean LDL-C reduction from baseline to week 12 was 28.9% with alirocumab, 150 mg, every 4 weeks (P = .0013), 31.54% with alirocumab, 200 mg, every 4 weeks (P = .0035), 42.53% with alirocumab, 300 mg, every 4 weeks (P < .0001), and 67.90% with alirocumab, 150 mg, every 2 weeks (P < .0001) versus 10.65% for placebo. Airocumab was well tolerated and achieved a substantial further reduction in LDL-C among HeFH patients with elevated LDL-C treated with high-dose statins with or without ezetimibe, thus

### TABLE 1

<table>
<thead>
<tr>
<th>Study</th>
<th>PCSK9 Mutation</th>
<th>LDL-C Reduction (%)</th>
<th>CHD Reduction (%)</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benn M et al</td>
<td>R46L</td>
<td>13</td>
<td>30</td>
<td>CCHS N = 10,032</td>
</tr>
<tr>
<td>Cohen J et al (ARIC Study)</td>
<td>R46L</td>
<td>15</td>
<td>47</td>
<td>N = 3363; white patients N = 9524</td>
</tr>
<tr>
<td></td>
<td>Y142X</td>
<td>28</td>
<td>88</td>
<td>N = 9654</td>
</tr>
<tr>
<td></td>
<td>C679X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ARIC, Atherosclerosis Risk in the Community; CCHS, Copenhagen City Heart Study; CGPS, Copenhagen General Population Study; CIHDS, Copenhagen Ischemic Heart Disease Study; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9.
providing more optimal LDL-C control in these difficult-to-treat HeFH patients.

**Alirocumab Key Phase III Trials: The ODYSSEY Trial Program**

The phase III ODYSSEY trial program includes 14 global trials with more than 23,500 patients enrolled across more than 2000 study centers. The trial components include ODYSSEY FH I, II, and HIGH FH; ODYSSEY MONO; ODYSSEY COMBO I and II; ODYSSEY LONG TERM; ODYSSEY CHOICE I and II; ODYSSEY ALTERNATIVES; ODYSSEY OPTIONS I and II; ODYSSEY OUTCOMES; and ODYSSEY OLE.

The ODYSSEY FH I, II, and HIGH FH trials assessed efficacy and safety in HeFH subjects with treatment target goals of LDL-C level 100 mg/dL (high-risk patients) or < 70 mg/dL (very high-risk patients).58-59 Alirocumab dosed at 75 or 150 mg every 2 weeks significantly reduced LDL-C from baseline to week 24 (48.8% [ODYSSEY FH I] and 48.7% [ODYSSEY FH II], respectively) compared with an increase in the placebo arms (9.1% [ODYSSEY FH I] and 2.8% [ODYSSEY FH II], respectively; \( P < .0001 \) for all comparisons).59-61 By week 24 (Figure 6), more alirocumab-treated patients (vs placebo-treated patients) reached LDL-C treatment goals providing more optimal LDL-C control in these difficult-to-treat HeFH patients.

**TABLE 2**

**LDL-C–lowering Efficacy of Alirocumab on a Statin Background: Phase II Studies**

<table>
<thead>
<tr>
<th>Dose of Alirocumab (mg)</th>
<th>Baseline LDL-C (mean) (mg/dL)</th>
<th>Observed Final LDL-C (mg/dL)</th>
<th>Reduction in LDL-C (%)</th>
<th>Absolute Change (mg/dL)</th>
<th>Duration (wk)</th>
<th>Background Therapy</th>
<th>Primary Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 Q2W</td>
<td>120.6</td>
<td>40.0</td>
<td>66.2</td>
<td>80.2</td>
<td>8</td>
<td>Atorvastatin (10 mg)</td>
<td></td>
</tr>
<tr>
<td>100 Q2W</td>
<td>127.0</td>
<td>46.0</td>
<td>64.2</td>
<td>81.0</td>
<td>12</td>
<td>Atorvastatin (10-40 mg)</td>
<td>change from baseline</td>
</tr>
<tr>
<td>150 Q2W</td>
<td>123.9</td>
<td>34.2</td>
<td>72.4</td>
<td>89.7</td>
<td></td>
<td>LDL-C was calculated</td>
<td></td>
</tr>
<tr>
<td>200 Q4W</td>
<td>128.2</td>
<td>71.1</td>
<td>43.2</td>
<td>57.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>300 Q4W</td>
<td>131.6</td>
<td>66.0</td>
<td>47.7</td>
<td>65.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>150 Q2W</td>
<td>147.3</td>
<td>50.3</td>
<td>67.9</td>
<td>97.0</td>
<td>12</td>
<td>Maximum tolerated dose</td>
<td></td>
</tr>
<tr>
<td>150 Q4W</td>
<td>167.1</td>
<td>120.7</td>
<td>28.9</td>
<td>46.4</td>
<td></td>
<td>of statin ± ezetimibe</td>
<td></td>
</tr>
<tr>
<td>200 Q4W</td>
<td>170.2</td>
<td>112.6</td>
<td>31.5</td>
<td>57.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>300 Q4W</td>
<td>140.0</td>
<td>82.8</td>
<td>42.5</td>
<td>57.2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; Q2W, every other week; Q4W, every 4 weeks.

![Figure 6. ODYSSEY FH I and FH II. Most heterozygous familial hypercholesterolemia patients receiving alirocumab on background statin ± other lipid-lowering therapy achieved low-density lipoprotein cholesterol (LDL-C) goals. ODYSSEY FH I, Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy; ODYSSEY FH II, Study of Alirocumab (REGN727/SAR236553) in Patients With HeFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT [Lipid-Modifying Therapy].](image)
events occurred with a similar incidence in the alirocumab- and placebo-treated groups (74.8% vs 75.4%). Final results from the ODYSSEY HIGH FH clinical trial showed a reduction of LDL-C of 46% with alirocumab versus 6.6% in the placebo group in patients on maximally tolerated statin plus other LLT.58

The ODYSSEY MONO trial assessed efficacy and safety of alirocumab as monotherapy versus ezetimibe in patients not receiving statins or other LLT.59,62 Mean LDL-C reductions at week 24 were 47.3% with alirocumab versus 15.6% with ezetimibe ($P < .0001$) by intent-to-treat analysis and 54.2% versus 17.2%, respectively, by on-treatment analysis ($P < .0001$).62 Adverse events were comparable between treatment groups.

The ODYSSEY COMBO I and II trials evaluated the efficacy and safety of alirocumab as add-on therapy to stable, maximally tolerated daily statin therapy versus ezetimibe in patients with hypercholesterolemia at high risk of ASCVD.59,63,64 In the ODYSSEY COMBO II trial, alirocumab lowered LDL-C levels significantly more than ezetimibe by week 24 (50.6% vs 20.7%; $P < .0001$) and week 52 (49.5% vs 18.3%; $P < .001$) (Figure 7).59,64 In addition, 77% of alirocumab-treated patients achieved LDL-C levels of ≤70 mg/dL by week 24 versus 45.6% of ezetimibe-treated patients ($P < .0001$).59,64 The percentage of adverse events was similar between alirocumab (71.2%) and ezetimibe (67.2%) treatments.59 ODYSSEY COMBO I evaluated LDL-C in high-CV risk subjects on maximally tolerated statin therapy with or without other LLT. Eligible subjects were randomly assigned to treatment with either alirocumab, 75 mg, every 2 weeks or placebo. If LDL-C was ≥70 mg/dL at week 8, study drug dose was increased to 150 mg every 2 weeks. ODYSSEY COMBO I demonstrated that (1) alirocumab reduced LDL-C from baseline to week 24 by 48% (vs 2% placebo; $P < .0001$) and LDL-C reduction was maintained through 52 weeks of therapy; (2) a “treat-to-target” approach resulted in 83% of subjects not requiring a dose increase to 150 mg and almost 80% achieving target LDL-C <70 mg/dL at week 24; (3) the incidence of adverse events was similar between alirocumab and placebo.65

The ODYSSEY LONG TERM trial assessed the long-term safety and tolerability of alirocumab for the treatment of high- and very high-CV risk patients with HeFH and ASCVD who were not adequately controlled on lipid-modifying therapy.59 By 24 weeks of treatment (Figure 8A), mean LDL-C was reduced from baseline by 61% for alirocumab versus an increase of 0.8% for patients treated with placebo ($P < .0001$).64 By week 24 (Figure 8B), more alirocumab-treated patients (vs placebo-treated patients) reached LDL-C goals of ≤50% reduction from baseline (76% vs 2%; $P < .0001$); LDL-C level <100 mg/dL in high-risk patients or <70 mg/dL in very high-risk patients (81% vs 9%; $P < .0001$).64 Safety analysis showed that adverse events were similar in both treatment arms (78.6% alirocumab and 80.6% placebo).59,66 A post-hoc analysis of ODYSSEY LONG TERM (Figure 8C) showed a lower rate of major CV events (cardiac death, MI, stroke, and unstable angina requiring hospitalization) in the alirocumab arm versus placebo (54% reduction over 65 weeks; $P < .01$).59,66

ODYSSEY CHOICE I and II are ongoing double-blind, placebo-controlled RCTs (duration, 12 months) evaluating alirocumab in...
inability to take at least two different statins because of muscle-related adverse effects, one of which must have been administered at the lowest-approved starting dose. Patients first received single-blind subcutaneous or oral placebo for 4 weeks and were withdrawn if they developed muscle-related adverse effects during placebo treatment. Continuing patients were randomized (2:2:1 ratio) to alirocumab, with a statin. The primary efficacy endpoint is a greater mean percentage LDL-C reduction in alirocumab-treated patients from baseline to 24 weeks (vs statin therapy). ODYSSSEY ALTERNATIVE assessed the efficacy and safety of alirocumab compared with ezetimibe in statin-intolerant patients at moderate to very-high ASCVD risk. Intolerance was defined as two dosages (75 mg every 2 weeks and 300 mg every 4 weeks) versus placebo with a 2:1:4 randomization. The trial objectives are to demonstrate LDL-C reduction with alirocumab at a starting dose of 150 mg every 4 weeks as add-on to nonstatin lipid-modifying background therapy or when administered as monotherapy versus placebo in patients with primary hypercholesterolemia not treated with a statin. The primary efficacy endpoint is a greater mean percentage LDL-C reduction in alirocumab-treated patients from baseline to 24 weeks (vs statin therapy). ODYSSSEY ALTERNATIVE assessed the efficacy and safety of alirocumab compared with ezetimibe in statin-intolerant patients at moderate to very-high ASCVD risk. Intolerance was defined as inability to take at least two different statins because of muscle-related adverse effects, one of which must have been administered at the lowest-approved starting dose. Patients first received single-blind subcutaneous or oral placebo for 4 weeks and were withdrawn if they developed muscle-related adverse effects during placebo treatment. Continuing patients were randomized (2:2:1 ratio) to alirocumab.
Anti-PCSK9 Monoclonal Antibodies continued

75 mg, every 2 weeks, ezetimibe, 10 mg/d, or atorvastatin, 20 mg/d (statin rechallenge) for 24 weeks. The alirocumab dose was increased to 150 mg every 2 weeks at week 12 if the week 8 LDL-C level was ≥ 70 g/dL in the very high-CV risk patient population or ≥ 100 mg/dL in the medium and high-risk cohort.59,69 The primary endpoint was percentage change in LDL-C from baseline to week 24 by intent-to-treat analysis.59,69 Key findings included (1) a greater percentage reduction from baseline in LDL-C at 24 weeks with alirocumab versus ezetimibe (45% vs 14.6%, respectively); (2) LDL-C treatment target goal of LDL-C < 100 mg/dL was observed in 61% of alirocumab- versus 10% of ezetimibe-treated patients (P < .001); and (3) lipoprotein(a) [Lp(a)] was reduced by 25.9% with alirocumab versus 7.3% with ezetimibe (P < .001).70 The rate of study drug discontinuation due to adverse events was lower with alirocumab than with ezetimibe.

The ODYSSEY OPTIONS I and II are randomized, double-blind, active-controlled studies (duration, 24 weeks). The ODYSSEY OPTIONS I trial is evaluating LDL-C level reduction by alirocumab versus ezetimibe when administered as add-on therapy to atorvastatin compared with either doubling the atorvastatin dose or switching from atorvastatin to rosuvastatin.59,71 ODYSSEY OPTIONS II is evaluating LDL-C reduction by alirocumab versus ezetimibe when administered as add-on therapy to rosuvastatin compared with doubling the rosuvastatin dose.59,72 The primary efficacy endpoint was the mean percentage LDL-C reduction in alirocumab- versus statin-treated patients from baseline to week 24. ODYSSEY OPTIONS I showed that the addition of alirocumab as add-on to atorvastatin, 20 mg or 40 mg, or to rosuvastatin, 10 mg, produced significantly greater LDL-C reductions versus the addition of ezetimibe, doubling of the statin dose, or switch to rosuvastatin. There was no significant difference observed between adding alirocumab to an entry dose of rosuvastatin of 20 mg or doubling of the rosuvastatin dose.73

The ODYSSEY OUTCOMES trial is evaluating the effect of alirocumab on ASCVD event incidence in patients who have experienced a recent ACS event and are receiving medical and dietary management for dyslipidemia.59,74 The primary endpoint is major adverse CV events (a composite of death, nonfatal MI, ischemic stroke, and unstable angina requiring hospitalization) and the goal is to demonstrate significant reduction in CV outcomes with use of alirocumab.74 ODYSSEY OLE is an open-label study assessing the long-term safety of alirocumab when added to other LLT in patients with HeFH.75 It will also evaluate the long-term efficacy of alirocumab on multiple lipid parameters, as reflected by percentage change from baseline.

Evolocumab Clinical Trials

The key phase III clinical trials for evolocumab are components of the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations (PROFICIO) to assess LDL-C reduction and ASCVD outcomes. The component trials include the following trials: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS)-2; Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD)-2; Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy for Easing Lipid Levels (MENDEL)-2; LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-2; Durable Effect of PCSK9 Antibody Compared with Placebo (DESCARTES); Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA)-2; Open Label Study of Long Term Evaluation Against LDL-C (OSLER)-2; Further Cardiovascular Outcomes Research With PCSK9 Inhibition In Subjects With Elevated Risk (FOURIER); and Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOY). The FOURIER and GLAGOY trials are ongoing.

The GAUSS-2 trial assessed hyperlipidemic patients who were statin intolerant.76,77 Evolocumab (140 mg every 2 weeks or 420 mg monthly) reduced LDL-C from baseline by 53% and 56% when compared with ezetimibe (37%-39% reduction from baseline respectively; P < .001). Muscle-based adverse events occurred in 12% of evolocumab-treated patients versus 23% of ezetimibe-treated patients. Treatment-emergent adverse events and laboratory abnormalities were comparable across treatment groups.77 The RUTHERFORD-2 trial assessed and evaluated safety, tolerability, and efficacy of evolocumab dosing (140 mg every 2 weeks or 420 mg monthly) in HeFH patients.78 Key results showed that, compared with placebo, evolocumab at both dosing schedules showed significant reduction in mean LDL-C at week

300 • Vol. 15 No. 4 • 2014 • Reviews in Cardiovascular Medicine
The adverse event profile was similar between the placebo (74.2%) and evolocumab treatment groups (74.8%).

The TESLA-2 study assessed the safety, tolerability, and efficacy of evolocumab plus a statin in patients with homozygous familial hypercholesterolemia compared with those on statin therapy alone (plus placebo).

Compared with placebo, evolocumab reduced LDL-C by 30.9% at 12 weeks and no serious adverse side effects were noted.

The OSLER-2 trial is an ongoing study composed of patients from phase III trials and is assessing long-term safety and efficacy of evolocumab in an open-label study.

Evolocumab reduced LDL-C by 52.1%. Patients who discontinued evolocumab had

12 (every 2 weeks, 59.2%; monthly, 61.3%; both P < .0001). (Figure 9).

Evolocumab was well tolerated, with similar rates of adverse events as placebo.

The MENDEL-2 trial assessed stand-alone evolocumab treatment in patients with hyperlipidemia versus ezetimibe or placebo.

Evolocumab dosage regimens rapidly and markedly lowered LDL-C over 12 weeks compared with either placebo or ezetimibe (Figure 10).

The overall incidence of treatment-emergent adverse effects was comparable across treatment groups.

The LAPLACE-2 trial assessed adding evolocumab (140 mg every 2 weeks or 420 mg monthly) to medium- or high-intensity statin therapy versus ezetimibe for patients with hyperlipidemia.

In patients with hypercholesterolemia on background statin therapy, evolocumab every 2 weeks reduced LDL-C concentration between 66% and 75% compared with placebo at 10 to 12 weeks of treatment. Evolocumab administered monthly reduced LDL-C concentration between 63% and 75% versus placebo, whereas ezetimibe reduced LDL-C by 20% to 25% compared with placebo.

The DESCARTES trial evaluated the safety and efficacy of evolocumab 420 mg or placebo administered to subjects with fasting LDL-C ≥ 75 mg/dL and a range of CV risk when added to one of four different background LLT groups.

Evolocumab reduced LDL-C from baseline by 57% (Figure 11) and there was a 90% reduction in PCSK9 levels after 1 week on evolocumab.

The adverse event profile was similar between the placebo (74.2%) and evolocumab treatment groups (74.8%).

The TESLA-2 study assessed the safety, tolerability, and efficacy of evolocumab plus a statin in patients with homozygous familial hypercholesterolemia compared with those on statin therapy alone (plus placebo).

Compared with placebo, evolocumab reduced LDL-C by 30.9% at 12 weeks and no serious adverse side effects were noted.

The OSLER-2 trial is an ongoing study composed of patients from phase III trials and is assessing long-term safety and efficacy of evolocumab in an open-label study. Evolocumab reduced LDL-C by 52.1%. Patients who discontinued evolocumab had
LDL-C levels return to near baseline. Adverse and serious adverse events were observed in 81.4% and 7.1%, respectively, of evolocumab-treated patients, versus 73.1% and 6.3%, respectively, of individuals in the standard of care (SOC) group. The five most common adverse effects in the evolocumab versus SOC treatment groups were nasopharyngitis (12.2% vs 9.8%), upper respiratory tract infections (7.7% vs 7.6%), influenza (7.1% vs 5.2%), arthralgia (6.9% vs 4.3%), and back pain (6.5% vs 5.4%).

Two phase III clinical trials are ongoing. The FOURIER trial will assess how evolocumab plus statin therapy compares with statin therapy alone for treating 22,500 high-risk patients with hyperlipidemia. The GLAGOV trial will determine the effect of evolocumab on plaque atheroma volume in patients with CAD undergoing cardiac catheterization.

**Bococizumab**

Bococizumab is being assessed in phase III clinical trials: the Evaluation of RN316 in Reducing the Occurrence of Major Cardiovascular

---

Figure 10. MENDEL-2: mean percentage change in LDL-C from baseline, placebo versus ezetimibe. LDL-C, low-density lipoprotein cholesterol; MENDEL, Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy for Easing Lipid Levels; PCSK9, proprotein convertase subtilisin/kexin type 9; SC, subcutaneous. Reprinted with permission from Koren MJ et al.®
on-treatment serum Lp(a) levels and incident CVD. Both studies suggest that Lp(a) may be a marker for a residual risk for CV events even in patients on statin therapy and at LDL-C targets. The consistent and robust reductions of Lp(a) observed with PCSK9 inhibitors may represent an added benefit above and beyond the concurrent reductions in LDL-C and non-HDL-C levels.

Is There a Cholesterol Level That Is Too Low?

There have been reports of healthy individuals documented with LDL-C levels as low as 15 mg/dL due to genetic mutations. PCSK9 inhibitor studies are ongoing, and will determine if LDL-C lowering beyond what is observed with statin therapy provides incremental and safe CV protection. The LDL-C levels recommended in clinical trials may be as low as 25 to 50 mg/dL. In data from ODYSSEY Long Term, in 562 patients who had two consecutive LDL-C measures, there was no signal of any increase in treatment-emergent adverse events of special interest including neurologic and CV events or neurocognitive disorders over the course of this 18-month study.

Hypercholesterolemia Management and 2013 ACC/AHA Cholesterol Guidelines

The 2013 ACC/AHA guidelines recommend measuring LDL-C percentage change from baseline over LDL-C numerical target values based on CV risk. The guidelines show several groups in whom the benefits of moderate- to high-intensity statin monotherapy outweigh the risks: individuals with clinical ASCVD, individuals with...
baseline LDL-C ≥ 190 mg/dL, individuals age 40 to 75 years with type I or II diabetes and LDL-C between 70 and 189 mg/dL without clinical ASCVD, and individuals age 40 to 75 years without clinical ASCVD or type I or II diabetes and LDL-C between 70 and 189 mg/dL and an estimated 10-year ASCVD risk calculation of ≥ 7.5%. The guidelines also identify several groups in which statin benefits are not supported by clinical data (but can be considered according to clinical judgment):29 patients age < 40 years, patients age >75 years, hemodialysis patients, and patients with congestive heart failure. The guidelines suggested nonstatin therapies be considered for the following groups:29 patients who do not respond as expected to statins, patients who cannot tolerate recommended statin dose intensity, and patients who have statin intolerance.

Use of PCSK9 Inhibitors in Relation to 2013 ACC/AHA Guidelines

The 2013 ACC/AHA guidelines downplayed, to some extent, the potential nonstatin value for achieving desired LDL-C or non-HDL-C treatment goals because RCT evidence has not yet supported their use.29 However, the guidelines also identified high-priority research needs, including alternative ASCVD risk-reduction strategies for patients intolerant of or resistant to statin therapy. Since publication of the guidelines, PCSK9 inhibitors have shown efficacy in lowering LDL-C levels while demonstrating their safety in use in numerous clinical trials. Thus, PCSK9 inhibitors may provide an effective treatment for patients who are statin intolerant or who do not reach therapeutic goals due to genetic abnormalities such as HeFH.

Conclusions

To reduce CV risk, LDL-C reduction remains the primary target for lipid modification. Many patients, including those with HeFH, are not able to reach LDL-C treatment goals with statins due to intolerance or resistance. PCSK9 inhibitors increase the functional half-life of the LDL-R and lead to increased removal of LDL-C from the circulation. PCSK9 inhibitors are effective either as monotherapy or as an adjunct to other LiTs and reduce LDL-C levels by 50% to 70%. Furthermore, PCSK9 mAbs appear to be well tolerated and safe. Signals are appearing in clinical trials that suggest a substantial incremental reduction of CV events with PCSK9 inhibition above and beyond that related to statins. Large RCTs with CV events as the primary endpoint are in progress (ODYSSEY OUTCOMES, FOURIER, and SPIRE) and should provide us with a wealth of information on their impact on CV events.

Dr. Kereiakes, Dr. Conterras, and Dr. Desai have no real or apparent conflicts of interest. Dr. Lepor has received grant/research support from sanofi-aventis (Bridgewater, NJ), Regeneron (Tarrytown, NY), and Amgen (Thousand Oaks, CA), and honoraria from sanofi-aventis and Regeneron.

References


304 • Vol. 15 No. 4 • 2014 • Reviews in Cardiovascular Medicine
signals are appearing in clinical trials that suggest a substantial incremental reduction of cardiovascular events with PCSK9 inhibition above and beyond those related to statins.

large randomized clinical trials with cardiovascular events as the primary endpoint are in progress: ODYSSEY OUTCOMES, FOURIER, and SPIRE.

anti-PCSK9 monoclonal antibodies

main points

• to reduce cardiovascular risk, low-density lipoprotein cholesterol (LDL-C) reduction remains the primary target for lipid modification.

• Many patients are not able to reach LDL-C treatment goals with statins due to intolerance or resistance, particularly those with heterozygous familial hypercholesterolemia.

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors increase the functional half-life of the LDL receptor, leading to increased removal of LDL-C from the circulation. PCSK9 inhibitors are effective either as monotherapy or as an adjunct to other lipid-lowering therapies, reducing LDL-C levels 50% to 70%, and appear to be well tolerated and safe.

• Signals are appearing in clinical trials that suggest a substantial incremental reduction of cardiovascular events with PCSK9 inhibition above and beyond those related to statins.

• Large randomized clinical trials with cardiovascular events as the primary endpoint are in progress: ODYSSEY OUTCOMES, FOURIER, and SPIRE.
Anti-PCSK9 Monoclonal Antibodies continued


